---
title: "Curis Lifesciences Ltd (CURIS) — Share Price, Financials & Analysis"
symbol: "CURIS"
company: "Curis Lifesciences Ltd"
canonical: "https://tapetide.com/stocks/CURIS"
isin: "INE1BZN01016"
nse_symbol: "CURIS"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 160.35
generated_at: "2026-09-13T18:47:03.211Z"
---

# Curis Lifesciences Ltd (CURIS)

Canonical page: https://tapetide.com/stocks/CURIS

## Company

- **NSE Symbol:** CURIS
- **ISIN:** INE1BZN01016
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2025-11-14
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** curisls.com

## About

Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.[1]

## Latest Price

- **Price:** ₹198.35
- **Change:** -10.4 (-4.98%)
- **Open:** ₹199.55
- **Day High:** ₹199.55
- **Day Low:** ₹198.35
- **Previous Close:** ₹208.75
- **Volume:** 21000
- **As Of:** 2026-09-11T07:45:29+00:00

## Key Fundamentals

Observed at 2026-09-11T04:40:41.563483Z.

- **Market Cap:** ₹160.35 Cr
- **Classification:** SME
- **P/E (reported):** 24.4
- **Book Value:** ₹58.57
- **Price to Book:** 3.56
- **Dividend Yield:** 0%
- **ROE:** 37.62%
- **ROCE:** 37.56%
- **Debt to Equity:** 0.46
- **Revenue (yearly):** ₹60.63 Cr
- **Net Income:** ₹6.93 Cr
- **EBITDA:** ₹11.12 Cr
- **52-Week High:** ₹228.8
- **52-Week Low:** ₹83.6

## Key Insights

### Strengths

- Company has a good return on equity (ROE) track record: 3 Years ROE 39.0%

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
- Working capital days have increased from 123 days to 232 days

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -728.57% | -152.54% | -106.63% |
| ebitda margin growth | 92.86% | -9.78% | -25.1% | 20.61% |
| net income growth | 20% | 13.61% | 78% | — |
| revenue growth | -19.47% | 22.24% | 20% | 20.57% |
| roce | — | -29.27% | 37.53% | 35.63% |
| roe | — | -60.11% | 170.7% | -90.1% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Sales | 15.9 | 34.36 | 27.91 | 32.72 |
| Expenses | 12.09 | 27.43 | 21.92 | 27.58 |
| Operating Profit | 3.81 | 6.93 | 5.99 | 5.14 |
| OPM % | 23.96 | 20.17 | 21.46 | 15.71 |
| Other Income | -0.02 | 0.05 | 0 | 0.27 |
| Interest | 0.5 | 0.61 | 0.43 | 0.71 |
| Depreciation | 0.34 | 0.34 | 0.34 | 0.35 |
| Profit before tax | 2.95 | 6.03 | 5.22 | 4.35 |
| Tax % | 25.42 | 33.67 | 19.35 | 37.7 |
| Net Profit | 2.2 | 4 | 4.21 | 2.71 |
| EPS in Rs | 44 | 6.74 | 7.09 | 3.35 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Sales | 23.7 | 35.21 | 35.13 | 49.13 | 60.63 |
| Expenses | 20.12 | 31.95 | 26.74 | 39.59 | 49.5 |
| Operating Profit | 3.58 | 3.26 | 8.39 | 9.54 | 11.13 |
| OPM % | 15.11 | 9.26 | 23.88 | 19.42 | 18.36 |
| Other Income | 0.02 | 0.34 | 0.31 | 0.51 | 0.27 |
| Interest | 1.62 | 1.33 | 0.85 | 1.11 | 1.14 |
| Depreciation | 0.75 | 0.73 | 0.68 | 0.67 | 0.7 |
| Profit before tax | 1.23 | 1.54 | 7.17 | 8.27 | 9.56 |
| Tax % | 59.35 | 20.13 | 32.22 | 26.24 | 27.62 |
| Net Profit | 0.49 | 1.23 | 4.87 | 6.11 | 6.92 |
| EPS in Rs | 9.8 | 24.6 | 97.4 | 10.3 | 8.56 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Equity Capital | 0.5 | 0.5 | 0.5 | 5.93 | 8.08 |
| Reserves | -1.4 | -0.18 | 5.37 | 10.29 | 39.27 |
| Borrowings | 17.62 | 16.19 | 17.09 | 15.61 | 21.59 |
| Other Liabilities | 10.68 | 13.16 | 10.91 | 10.7 | 12.58 |
| Total Liabilities | 27.4 | 29.67 | 33.87 | 42.53 | 81.52 |
| Fixed Assets | 12.33 | 12.2 | 11.59 | 10.99 | 10.77 |
| CWIP | 0 | 0 | 0 | 0.02 | 1.33 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Other Assets | 15.06 | 17.46 | 22.27 | 31.51 | 69.41 |
| Total Assets | 27.4 | 29.67 | 33.87 | 42.53 | 81.52 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 4.95 | 3.35 | 0.28 | -1.76 | -16.42 |
| Cash from Investing Activity | -0.37 | -0.55 | -0.06 | -0.02 | -1.59 |
| Cash from Financing Activity | -4.58 | -2.76 | 0.05 | 1.67 | 20.87 |
| Net Cash Flow | -0.01 | 0.04 | 0.27 | -0.11 | 2.86 |
| Free Cash Flow | 4.56 | 2.77 | 0.21 | -1.85 | -18.22 |
| CFO/OP | 138 | 103 | 3 | -2 | -127 |

### Ratios

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Debtor Days | 96.1 | 98.17 | 104.94 | 55.87 | 67.55 |
| Inventory Days | 208.46 | 114.92 | 273.22 | 347.26 | 297 |
| Days Payable | 359.58 | 262.67 | 210.4 | 112.29 | 71.22 |
| Cash Conversion Cycle | -55.01 | -49.58 | 167.75 | 290.83 | 293.32 |
| Working Capital Days | -16.02 | -20.84 | 36.26 | 99.63 | 232.2 |
| ROCE % | — | 17.21 | 40.64 | 34.24 | 21.25 |

## Shareholding Pattern

### Quarterly

| Category | Dec 2024 | Jun 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Promoters | 92.68% | 92.68% | 68.03% |
| FIIs | 0% | 0% | 1.19% |
| DIIs | 0% | 0% | 5.8% |
| Government | 0% | 0% | 0% |
| Public | 4.37% | 0% | 14.38% |
| Others | 2.95% | 7.32% | 10.6% |
| No. of Shareholders | 27 | 35 | 340 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 11 / 6 / 2

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 170.27 | Buy |
| EMA (10) | 176.81 | Buy |
| SMA (20) | 145.57 | Buy |
| EMA (20) | 155.74 | Buy |
| SMA (50) | 121.76 | Buy |
| EMA (50) | 133.03 | Buy |
| SMA (100) | 118.25 | Buy |
| EMA (100) | 123.69 | Buy |
| SMA (200) | — | Neutral |
| EMA (200) | — | Neutral |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 76.3 | Sell |
| MACD (12,26,9) | 23.09 | Buy |
| Stochastic (14,3,3) | 84.18 | Sell |
| ADX (14) | 59.9 | Buy |
| Williams %R (14) | -28.62 | Neutral |
| ATR (14) | 10.73 | High Volatility |
| ROC (12) | 57.92 | Buy |
| Stoch RSI (14) | 36.38 | Neutral |
| UO (7,14,28) | 66.56 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 Jul - Clarifies March 31, 2026 results filing; submits consolidated PDF and corrected XBRL. | [Reply to Clarification- Financial results 9 Jul - Clarifies March 31, 2026 results filing; submits consolidated PDF and corrected XBRL.](https://nsearchives.nseindia.com/corporate/CURIS_08072026104657_Revised_financial_results_final_NT.pdf) |
| 8 Sep - Curis Lifesciences will hold its 10th AGM on 29 September 2026 via VC/OAVM; remote e-voting details published. | [Copy of Newspaper Publication 8 Sep - Curis Lifesciences will hold its 10th AGM on 29 September 2026 via VC/OAVM; remote e-voting details published.](https://nsearchives.nseindia.com/corporate/CURIS_08092026123901_Newspapaer_Intimation_signed.pdf) |
| 8 May 2026 - Curis Lifesciences says it is not a large corporate; outstanding borrowing was nil on 31 March 2026. | [Updates 8 May 2026 - Curis Lifesciences says it is not a large corporate; outstanding borrowing was nil on 31 March 2026.](https://nsearchives.nseindia.com/corporate/CURIS_08052026172658_Intitial_Disclosure_Large_entity.pdf) |
| 7 Sep - Board approved FY26 Director’s Report, AGM notice, related party transactions; 10th AGM on 29 September 2026. | [Outcome of Board Meeting 7 Sep - Board approved FY26 Director’s Report, AGM notice, related party transactions; 10th AGM on 29 September 2026.](https://nsearchives.nseindia.com/corporate/CURIS_07092026185951_Outcome_of_BM.pdf) |
| 7 Sep - 10th AGM on 29 Sep 2026; FY2025-26 annual report submitted. | [Shareholders meeting 7 Sep - 10th AGM on 29 Sep 2026; FY2025-26 annual report submitted.](https://nsearchives.nseindia.com/corporate/CURIS_07092026192842_Intimation_of_AGM_Final.pdf) |
| 31 March 2026 - Ms. Dhruvi Shyam Kapadia resigned as Independent Director effective 01.04.2026 due to increased commitments; no other material reasons. | [Resignation 31 March 2026 - Ms. Dhruvi Shyam Kapadia resigned as Independent Director effective 01.04.2026 due to increased commitments; no other material reasons.](https://nsearchives.nseindia.com/corporate/CURIS_31032026181949_Intimation_Regarding_Resignation_Dhruvi_NT.pdf) |
| 31 March 2026 - Curis Lifesciences Limited has informed regarding Resignation of Dhruvi Shyam Kapadia as Independent Director of the company w.e.f. April 01, 2026. | [Resignation 31 March 2026 - Curis Lifesciences Limited has informed regarding Resignation of Dhruvi Shyam Kapadia as Independent Director of the company w.e.f. April 01, 2026.](https://nsearchives.nseindia.com/corporate/CURIS_31032026183106_Intimation_Regarding_Resignation_Dhruvi_NT_Signed.pdf) |
| 31 March 2026 - CURIS LIFESCIENCES LIMITED has informed about Resignation of Independent director. | [Resignation of Independent director 31 March 2026 - CURIS LIFESCIENCES LIMITED has informed about Resignation of Independent director.](https://nsearchives.nseindia.com/corporate/CURIS_ROID_81472_KMP_Doc.zip) |
| 30 May 2026 - Submitted SDD compliance certificate for year ended 31 March 2026; no non-compliances reported. | [Structural Digital Database 30 May 2026 - Submitted SDD compliance certificate for year ended 31 March 2026; no non-compliances reported.](https://nsearchives.nseindia.com/corporate/CURIS_30052026142725_SDD_Compliance_certificate.pdf) |
| 30 May 2026 - Curis filed FY26 IPO proceeds utilization statement for ₹27.52 crore; no deviation reported. | [Statement of deviation(s) or variation(s) under Reg. 32 30 May 2026 - Curis filed FY26 IPO proceeds utilization statement for ₹27.52 crore; no deviation reported.](https://nsearchives.nseindia.com/corporate/CURIS_30052026212025_Final_variation_in_proceeds.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Jan 2026 | [Concall - Jan 2026](https://nsearchives.nseindia.com/corporate/CURIS_09012026184458_Intimation_regarding_outcom_of_investor_meet_recording_link.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:47:03.211Z.